Health ProductsDear Healthcare Professional Letter

Apo-Mycophenolic Acid 360 mg (DIN 02372746 Lot KY6601) - Recall of One Lot due to French Labelling Error - For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Issue: Labelling and Packaging
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Apotex Inc. Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Health Canada Endorsed Important Safety Information on APO-MYCOPHENOLIC ACID 360 MG

August 15, 2014

Dear Healthcare Professional,

Subject: Recall of one lot of APO-MYCOPHENOLIC ACID (DIN: 02372746, Lot # KY6601) due to incorrect tablet strength labelling on the French side panel of the Blister Carton of 360mg pack.

Apotex Inc, in collaboration with Health Canada, would like to inform you that it is recalling one lot (Lot # KY6601) of Apo-Mycophenolic Acid 360 mg tablets. The product is being recalled due to an incorrectly labelled tablet strength  on the French side panel of the Blister Carton of the 120 tablet pack, which may pose a risk of potential dosing error. The English version is accurate and identifies the strength correctly as 360 mg tablets. The French side panel incorrectly states 180 mg instead of 360 mg however, the dosage directions in the French statement are correct. The tablet strength indicated on the inner blister packs are correctly labelled, and each tablet is engraved with “MYC 360” on one side.

  • Apotex is recalling one lot of Apo-Mycophenolic Acid 360 mg tablets (Lot # KY6601). Healthcare practitioners should be aware that the tablet strength indicated on the French side panel of the Blister Carton of the 120 tablet pack incorrectly states 180 mg instead of 360 mg, posing a risk of potential dosing error.
  • In the event that the patient takes more than the recommended dose, potential adverse effects include over-suppression of the immune system and increased susceptibility to infections (including opportunistic infections, fatal infections and sepsis), hematological abnormalities and gastrointestinal symptoms.
  • Customers can return the impacted units of lot KY6601 by contacting Stericycle as follows;
    Event #: 6560
    Stericycle Inc.
    25 Ironside Crescent,
    Toronto, Ontario M1X 1G5
    Toll-free FAX: 1-855-497-9850
    Toll Free Call number: 1-855-328-6654

Apo-Mycophenolic Acid is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids. The recommended adult dose is 720 mg twice a day for a total daily dose of 1440 mg.

Managing marketed health product-related adverse reactions depends on healthcare professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of dosing error or other serious or unexpected adverse reactions in patients receiving Apo-Mycophenolic Acid tablets should be reported to Apotex Inc. or Health Canada. 

Apotex Inc.
150 Signet Drive
Weston, Ontario
M9L 1T9
Phone: 1-800-667-4708
Fax: 1-416-401-3819
Email:Drugsafety@apotex.com

To correct your mailing address or fax number, contact Apotex Inc.

You can report any suspected adverse reactions associated with the use of health products to Health Canada by:

  • Calling toll-free at 1-866-234-2345; or
     
  • Visiting MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.

For other health product inquiries related to this communication, please contact Health Canada at:
Health Products and Food Branch Inspectorate
E-mail: DCVIU_UVCEM@hc-sc.gc.ca
Telephone : 1-800-267-9675
Fax : 1-613-946-5636

Yours sincerely,

Original signed by
    
Colin D’Cunha MBBS, MHSc, FRCPC      
Director, Global Medical Affairs 
Apotex Inc.       

References:

1 Apo-Mycophenolic Acid Product Monograph. Apotex Inc. 2013.

For more information

The manufacturer advised Health Canada of the risk associated with this health product, and has recalled the impacted product. Health Canada supports the actions taken by the manufacturer and as such a risk assessment was not required and a Summary Safety Review was not prepared.
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime